Can Afamelanotide and Teriparatide be used together?

There is no clinical evidence or established rationale for combined use, as they target completely different systems (skin melanin production vs. bone formation). Co-administration has not been studied. Any combined therapy would require explicit medical supervision and is not standard practice.

Which has more clinical trial data?

Teriparatide has significantly more trial support: 176 completed trials versus 23 for afamelanotide. Teriparatide has also been available longer (FDA-approved 2002 vs. 2014), giving it a longer real-world safety record in large patient populations.

Are both available in Canada?

No. Teriparatide is Health Canada approved and available. Afamelanotide is not approved in Canada, though patients with EPP may access it through special programs or cross-border import in some cases. Consult a Canadian physician for current options.

How long do I need to use each one?

Afamelanotide is typically used continuously during high-risk sun seasons or year-round for severe EPP; it can be paused without loss of benefit if sun exposure is minimized. Teriparatide is recommended for a maximum of 24 months of continuous treatment, though bone benefits can persist after stopping.

What are the main safety concerns for each?

Afamelanotide requires skin monitoring due to pigmentation changes and mole darkening; it's contraindicated in those at high melanoma risk. Teriparatide carries a black box warning for osteosarcoma (observed in rats, not humans) and can cause hypercalcemia; it's contraindicated in patients with Paget's disease or prior radiation therapy to the skeleton.

Afamelanotide vs Teriparatide: Key Differences

Afamelanotide and Teriparatide are both FDA-approved peptide therapeutics, but they work in completely different systems and treat different conditions. Afamelanotide is a melanocortin receptor agonist designed to stimulate melanin production for erythropoietic protoporphyria (EPP) and other photosensitivity disorders. Teriparatide is a parathyroid hormone analogue that stimulates bone formation, primarily used for osteoporosis. While both are approved peptides with strong clinical evidence (Grade A for each), they have almost no clinical overlap—choosing between them depends entirely on what condition you're addressing. This guide breaks down how they differ in mechanism, evidence, regulatory status, and ideal use cases.

What Is Afamelanotide?

Afamelanotide (brand name Scenesse) is a synthetic peptide that activates melanocortin-1 (MC1) receptors on melanocytes, the cells responsible for producing melanin. By stimulating melanin synthesis and deposition in the skin, afamelanotide helps patients produce a natural, protective tan—even without sun exposure.

The compound was developed specifically for erythropoietic protoporphyria (EPP), a rare genetic disorder where patients have severe photosensitivity. EPP causes immediate pain, burning, and swelling when skin is exposed to sunlight, severely limiting outdoor activity. Afamelanotide helps by increasing skin melanin content, which acts as a natural photoprotectant.

Regulatory Status:

FDA-approved (2014)
EMA-authorised (2014)
Not approved in Canada

Clinical Evidence: Afamelanotide has completed 23 clinical trials. A landmark Phase III trial published in The Lancet demonstrated that afamelanotide significantly reduced phototoxic reactions in EPP patients, with 74% of patients reporting fewer or no phototoxic episodes during treatment versus placebo.

What Is Teriparatide?

Teriparatide (brand name Forteo) is a synthetic recombinant human parathyroid hormone (PTH 1-34). It works by binding to PTH receptors on bone cells, stimulating both bone formation and remodeling. Unlike other osteoporosis drugs that slow bone loss, teriparatide actively builds new bone.

Teriparatide is used primarily for postmenopausal osteoporosis and men with osteoporosis at high fracture risk. It's also used off-label in some cases of hypoparathyroidism and delayed fracture healing, though evidence for these indications varies.

Regulatory Status:

FDA-approved (2002)
EMA-authorised (2003)
Health Canada approved (2004)

Clinical Evidence: Teriparatide has the strongest trial portfolio of the two, with 176 completed clinical trials. The landmark Fracture Prevention Trial (FPT) showed that teriparatide reduced the risk of new vertebral fractures by 65% and non-vertebral fractures by 53% in postmenopausal women with osteoporosis over 19 months.

Head-to-Head: Key Differences

Mechanism of Action

| Feature | Afamelanotide | Teriparatide | |---------|---|---| | Target | Melanocortin-1 receptors on skin cells | Parathyroid hormone receptors on bone | | Effect | Increases melanin production | Stimulates bone formation | | System | Dermatological/photosensitivity | Skeletal/metabolic |

Primary Indications

Afamelanotide:

Erythropoietic protoporphyria (EPP)
Possibly other porphyrias with photosensitivity (under investigation)

Teriparatide:

Postmenopausal osteoporosis
Osteoporosis in men
Glucocorticoid-induced osteoporosis
Hypoparathyroidism (approved for a similar formulation, Natpara)

There is no clinical overlap—they treat entirely different conditions in different tissues.

Route of Administration

Afamelanotide: Subcutaneous implant (one small rod under the skin, replaced every 60 days)

Teriparatide: Daily subcutaneous injection (self-administered once daily)

Duration of Effect

Afamelanotide: Sustained melanin production throughout the implant cycle; effects persist for several weeks after removal

Teriparatide: Requires daily dosing; effects plateau after approximately 24 months of continuous use; FDA recommends a maximum of 2 years of treatment due to rat studies showing bone tumors at very high doses over extended periods (not seen in humans to date)

Side Effect Profiles

Afamelanotide:

Darkening of moles or other pigmented lesions (monitored closely)
Nausea (especially early in treatment)
Headache
Injection site reactions
Requires baseline and periodic skin exams

Teriparatide:

Leg cramps
Nausea
Dizziness
Orthostatic hypotension (drop in blood pressure when standing)
Hypercalcemia (elevated calcium) in some patients
Black box warning regarding osteosarcoma risk (observed in rats; not established in humans)

Cost and Access

Both are expensive specialty medications. Afamelanotide is primarily used for a rare disease, so it's less widely prescribed but often covered for EPP. Teriparatide is more common in osteoporosis treatment and generally has broader insurance coverage due to the prevalence of osteoporosis.

Evidence Comparison

Both compounds carry Grade A evidence (rigorous clinical trial data), but in different populations:

Afamelanotide Evidence:

23 trials total
Strong efficacy data in EPP specifically
Limited data in other indications
A 2015 meta-analysis confirmed benefit in photosensitivity disorders

Teriparatide Evidence:

176 trials total—substantially larger trial portfolio
Longest track record (approved since 2002)
Efficacy demonstrated across multiple osteoporosis populations
Landmark data in fracture prevention remains the gold standard for bone-building therapy

Which Should You Consider?

Afamelanotide Is Best For:

Patients with erythropoietic protoporphyria (the primary approved indication)
People with severe photosensitivity who need a sustained, long-acting solution
Patients who prefer an implant over daily injections
Those who want to naturally build skin melanin as photoprotection

Teriparatide Is Best For:

Patients with postmenopausal or male osteoporosis at high fracture risk
People who have failed or are intolerant of other osteoporosis drugs
Those with glucocorticoid-induced bone loss
Patients with hypoparathyroidism (related compound Natpara is approved)
People willing to commit to daily self-injections

Related Peptides

If you're exploring peptide therapeutics, you might also investigate:

Semaglutide – A GLP-1 receptor agonist for metabolic health (entirely different mechanism)
Ipamorelin – A growth hormone secretagogue under investigation
Natpara – The approved formulation of PTH for hypoparathyroidism

For deeper context on how peptides work, see our guide to peptide receptors and bioavailability.

Bottom Line

Afamelanotide and Teriparatide are both well-researched, FDA-approved peptides with Grade A evidence—but they are used for completely different medical purposes. There is no scenario where you would choose between them: your condition, not preference, determines which is appropriate. If you have photosensitivity or EPP, afamelanotide may be relevant. If you have osteoporosis, teriparatide is a proven bone-building option. Always consult a specialist to determine which therapy aligns with your individual health profile.

Afamelanotide vs Teriparatide: What's the Difference?